HDAC3 and Miyoshi myopathy: MM serves as an example, as the pan-HDAC inhibitor panobinostat has been approved for the treatment of relapsed/refractory MM patients who had two prior lines of treatment [44] and since HDAC3 was recently identified as a novel therapeutic target in MM as HDAC3 inhibitors were shown to induce MM cell death [45].